Skip to main content

Table 4 Multivariate cox regression models for progression-free survival (PFS) and overall survival (OS) in the 33 cetuximab-treated patients

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

 

PFS

OS

HR

95 % CI

P value

HR

95 % CI

P value

Smoking history

  

0.268

  

0.786

 Ex-smoker

1.0

  

ND

  

 Smoker

2.2

0.2–20.9

 

ND

  

 Non-smoker

0.4

0.2–1.9

 

ND

  

Primary site

  

0.184

  

0.389

 Larynx

1.0

  

1.0

  

 Oropharynx

0.3

0.5–2.2

 

0.3

0.1–4.6

 

 Oral cavity

2.8

0.4–10.2

 

2.1

0.4–6.3

 

 Hypopharynx

2.1

0.3–8.3

 

2.6

0.1–10.2

 

Histological grade

  

0.090

  

0.719

 Well-differentiated

1.0

  

1.0

  

 Moderately differentiated

4.6

2.5–7.6

 

0.9

0.1–3.2

 

 Poorly differentiated

3.2

2.3–8.5

 

1.9

0.1–4.1

 

Alcohol

2.1

0.7–10.3

0.381

6.2

0.1–34.2

0.413

MET overexpression

7.6

4.6–10.4

0.060

4.9

0.1–8.5

0.070

p-MET overexpression

6.5

1.5–8.9

0.002

8.2

0.2–14.6

0.022

HGF overexpression

6.6

1.2–8.4

0.059

2.2

0.2–2.1

0.110

  1. Firstly, univariate analysis was performed for the descriptive variables, and then we executed a multivariate analysis on those significant variables. Since MET, p-MET and HGF expression are associated with each other, we performed separate analysis for each marker
  2. HR hazard ratio, CI confidence interval, ND not enough data available
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us